p53 Nuclear protein overexpression in colorectal cancer: A dominant predictor of survival in patients with advanced hepatic metastases

Journal of Clinical Oncology

Volumn 14, Issue 10, 1996, Pages 2696-2701

  Belluco, C ^a   Guillem, J G ^a   Kemeny, N ^a   Huang, Y ^a   Klimstra, D ^a   Berger, M F ^a   Cohen, A M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER SURVIVAL; COLORECTAL CANCER; DIAGNOSTIC VALUE; FEMALE; HUMAN; HUMAN TISSUE; LIVER METASTASIS; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK ASSESSMENT;

EID: 0029738119     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.10.2696     Document Type: Article

References (45)

1. Boring CC, Squires TS, Tong T: Cancer statistics 1993. CA 43:7-26, 1993
2. Weiss L, Grundmann E, Torhost J, et al: Hematogenous metastatic patterns in colonic carcinoma: An analysis of 1541 necropsies. J Pathol 150:195-203, 1986
3. Welch JP, Donaldson GA: Detection and treatment of recurrent cancer of the colon and rectum. Am J Surg 135:505-511, 1978
4. Hughes K, Scheele J, Sugarbaker PH: Surgery for colorectal cancer metastatic to the liver. Surg Clin North Am 69:340-359, 1989
5. Steele G, Ravikumar TS: Resection of hepatic metastases from colorectal cancer. Ann Surg 210:127-138, 1989
6. Kemeny N, Lokich JJ, Anderson N, et al: Recent advances in the treatment of advanced colorectal cancer. Cancer 71:9-18, 1993
7. Kemeny N, Cohen A, Bertino JR, et al: Continuous intrahepatic infusion of floxuridine and leucovorin through an implantable pump for the treatment of hepatic metastases from colorectal carcinoma. Cancer 65:2446-2450, 1989
8. Stang R, Altendorf-Hofmann A, Charneley RM, et al: Factors influencing the natural history of colorectal liver metastases. Lancet 343:1405-1410, 1994
9. Patt YZ: Regional hepatic arterial chemotherapy for colorectal cancer metastatic to the liver: The controversy continues. J Clin Oncol 11:815-819, 1993
10. Weinberg RA: The integration of molecular genetics into cancer management. Cancer 70:1653-1658, 1992
11. Fearon ER, Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 61:759-767, 1990
12. Cripps KJ, Purdie CA, Carder PJ, et al: A study of stabilization of p53 protein versus point mutation in colorectal adenocarcinoma. Oncogene 9:2739-2743, 1994
13. Dix B, Robbins P, Carrello S, et al: Comparison of P53 gene and protein overexpression in colorectal carcinomas. Br J Cancer 60:585-590, 1994
14. Levine AJ: The p53 tumor suppressor gene. Nature 351:453-456, 1991
15. Lane DP: The regulation of p53 function: Stein Award Lecture. Int J Cancer 57:623-627, 1994
16. Laurent-Puig P, Olschwang S, Delattre O, et al: Survival and acquired genetic alterations in colorectal cancer. Gastroenterology 102:1136-1141, 1992
17. Hamelin R, Laurent-Puig P, Olschwang S, et al: Association of p53 mutations with short survival in colorectal cancer. Gastroenterology 106:42-48, 1994
18. Kern SE, Fearon ER, Tersmette KWF, et al: Allelic loss in colorectal carcinoma. J Am Med Assoc 261:3099-3103, 1989
19. Yamaguchi A, Kurosaka Y, Fushida S, et al: Expression of P53 protein in colorectal cancer and its relationship to short-term prognosis. Cancer 70:2778-2784, 1992
20. Tomoda H, Kakeji Y: Immunohistochemical analysis of p53 in colorectal cancer regarding clinicopathological correlation and prognostic significance. J Surg Oncol 58:125-128, 1995
21. Remvikos Y, Tominaga O, Hammel P, et al: Increased P53 protein content of colorectal tumours correlates with poor survival. Br J Cancer 66:758-764, 1992
22. Starzynska T, Bromley M, Ghosh A, et al: Prognostic significance of P53 overexpression in gastric and colorectal carcinoma. Br J Cancer 66:558-562, 1992
23. Yamaguchi A, Nakagawara G, Kurosaka Y, et al: P53 immunoreaction in endoscopic biopsy specimens of colorectal cancer, and its prognostic significance. Br J Cancer 68:399-402, 1993
24. Auvinen A, Isola J, Visakorpi T, et al: Overexpression of P53 and long-term survival in colon carcinoma. Br J Cancer 70:293-236, 1994
25. Zeng ZS, Sarkis AS, Zhang ZF, et al: P53 nuclear overexpression: An independent predictor of survival in lymph node positive colorectal cancer patients. J Clin Oncol 12:2043-2050, 1994
26. Purdie CA, O'Grady J, Piris J, et al: P53 expression in colorectal tumors. Am J Pathol 138:807-813, 1991
27. Pignatelli M, Stamp GWH, Kafiri G, et al: Over-expression of P53 nuclear oncoprotein in colorectal adenomas. Int J Cancer 50:683-688, 1992
28. Hanski C, Bornhoeft G, Shimoda T, et al: Expression of P53 protein in invasive colorectal carcinomas of different histologic types. Cancer 70:2772-2777, 1992
29. Goh HS, Chan CS, Khine K, et al: P53 and behavior of colorectal cancer. Lancet 344:233-234, 1994
30. Bertorelle R, Esposito G, Del Mistro A. et al: Association of P53 gene and protein alterations with metastases in colorectal cancer. Am J Surg Pathol 19:463-471, 1995
31. Shaw P, Bovey R, Tardy S, et al: Induction of apoptosis by-wild type P53 in a human colon tumor-derived cell line. Proc Natl Acad Sci USA 89:4495-4499, 1992
32. Lane DP: A death in the life of P53. Nature 362:786-787, 1993
33. Clarke AR, Purdie CA, Harrison DJ, et al: Thymocyte apoptosis induced by P53-dependent and independent pathways. Nature 362:849-852, 1993
34. Lowe SW, Schmitt EM, Smith SW, et al: P53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362:847-849, 1993
35. Lowe SW, Ruley HE, Jacks T, et al: P53-Dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74:957-967, 1993
36. Lowe SW, Bodis S, McClatchey A, et al: P53 status and the efficacy of cancer therapy in vivo. Science 266:807-810, 1994
37. Chin KV, Ueda K, Pastan I, et al: Modulation of activity of the promoter of the human MDR1 gene by Ras and P53. Science 225:459-462, 1992
38. Zatstawny RL, Salvino R, Chen J, et al: The core promoter region of the P-glycoprotein gene is sufficient to confer differential responsiveness to wild type and mutant P53. Oncogene 8:1529-1535, 1993
39. American Joint Committee on Cancer: Manual for Staging of Cancer (ed 3). Philadelphia, PA, Lippincott, 1988
40. Morson BC, Sobin LH: Histologic Typing of Intestinal Tumours. WHO Technical Report 15. Geneva, Switzerland, World Health Organization, 1976
41. Banks L, Matlashewski G, Crawford L: Isolation of human-P53-specific monoclonal antibodies and their use in the studies of P53 expression. Eur J Biochem 159:529-534, 1986
42. Shi SR, Key ME, Kalra K: Antigens retrieval in formalin-fixed, paraffin-embedded tissues: An enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 39:741-748, 1991
43. Bartkova J, Bartek J, Vijtesek B, et al: Immunochemical analysis of the P53 oncoprotein in matched primary and metastatic human tumours. Eur J Cancer 29A:881-886, 1993
44. Fujiware T, Grimm EA, Mukhopadhyay T, et al: Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild type -53 gene. Cancer Res 54:2287-2291, 1994
45. Petty RD, Cree IA, Sutherland LA, et al: Expression of the p53 tumor suppressor gene product is a determinant of chemosensitivity. Biochem Biophys Res Commun 199:264-270, 1994